Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)

Inclusion Criteria: * Patients must agree to the study protocol and provide written informed consent * Outpatients ≥ 19 years, \<75 years of age, male or female * Non-diabetic or type 2 DM patients with HbA1c 7.0-10.5% * Patients with nonischemic cardiomyopathy (LVEF ≤40%) * Exclusion of ischemic origin cardiomyopathy using coronary angiography or CT angiography or SPECT scan (e.g. significant stenosis of proximal LAD or left main \& myocardial infarction) * Dyspnea of NYHA functional class II or III * NT-proBNP ≥ 400 pg/ml (≥ 900 pg/ml if atrial fibrillation or atrial flutter) * Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB or ARNI if indicated) for at least 4 weeks prior to study entry Exclusion Criteria: * History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug * Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor * Known history of angioedema * Current acute decompensated heart failure or dyspnea of NYHA functional class IV * Medical history of hospitalization within 6 weeks * Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months * Substantial myocardial ischemia requiring coronary revascularization therapy or a plan of coronary revascularization within 6 months * A plan of heart transplantation or implantation of cardi…